Global Metastatic Castrate Resistant Prostate Cancer Treatment Market, By Treatment (Hormone Therapies, Xofigo, Sipuleucel-T, Cabazitaxel, Docetaxel, and Others), Route of Administration (Oral, Parenteral, and Others), Form (Solid Dosage Form, Liquid Dosage Form), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031.
Metastatic Castrate Resistant Prostate Cancer Treatment Market Analysis and Size
In the metastatic castrate resistant prostate cancer (mCRPC) treatment market, therapeutic options for prostate cancer play a crucial role in addressing the complex needs of patients. These options include hormonal therapies targeting androgen receptors, chemotherapy agents such as docetaxel and cabazitaxel, and newer treatments such as immunotherapies and radioligand therapies. Each treatment for prostate cancer aims to manage symptoms, slow disease progression, and potentially extend survival in patients with advanced prostate cancer.
The global metastatic castrate resistant prostate cancer treatment market size was valued at USD 11.10 billion in 2023 and is projected to reach USD 20.70 billion by 2031, with a CAGR of 8.10% during the forecast period of 2024 to 2031.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Hormone therapies, Xofigo, Sipuleucel-T, Cabazitaxel, Docetaxel, and Others), Route of Administration (Oral, Parenteral, and Others), Form (Solid Dosage Form, Liquid Dosage Form), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Bausch Health Companies Inc. (Canada), Takeda Pharmaceutical Company Limited (Japan), AbbVie Inc. (U.S.), Merck KGaA (Germany)
|
|
Market Opportunities
|
|
Market Definition
Metastatic castration-resistant prostate cancer (mCRPC) treatment involves therapies designed for prostate cancer that has spread to other parts of the body and is no longer responsive to hormone therapy (castration-resistant). Treatment options typically include targeted therapies, chemotherapy, and recently FDA-approved radioligand therapies such as Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which selectively deliver radiation to cancer cells. The goal is to manage symptoms, prolong survival, and improve quality of life for patients with this advanced stage of prostate cancer.
Metastatic Castrate Resistant Prostate Cancer Treatment Market Dynamics
Drivers
- Growing Advancements in Therapy
Advancements in therapy include the development of novel hormonal therapies that target androgen receptor signaling pathways, immunotherapies that harness the immune system to fight cancer cells, and radioligand therapies such as Pluvicto, which deliver targeted radiation to cancer cells. Innovations in these therapies aim to slow disease progression and manage symptoms effectively and offer new hope for extending survival in patients with advanced prostate cancer. The evolving landscape of personalized medicine further tailors treatments to individual patient profiles by providing best prostate cancer treatment which enhances therapeutic efficacy and driving market growth through ongoing research and clinical advancements.
- Rising Prevalence of Prostate Cancer
As the global population ages and diagnostic capabilities improve, more cases of prostate cancer, including those progressing to metastatic and castration-resistant stages, are being diagnosed. This increasing incidence expands the patient pool requiring advanced treatment options such as targeted therapies, chemotherapy, and radioligand therapies. Pharmaceutical companies and healthcare providers are thus motivated to innovate and invest in developing new drugs and improving existing treatments to meet the growing demand and improve patient outcomes.
Opportunities
- Expanding Government Initiatives
Governments worldwide often allocate substantial funding towards cancer research, treatment infrastructure development, and public health campaigns aimed at early detection and awareness. These initiatives foster collaboration between healthcare providers, research institutions, and pharmaceutical companies, accelerating the development and adoption of innovative therapies. Additionally, regulatory bodies implement policies to streamline drug approvals and enhance patient access to advanced treatments.
- Rising Healthcare Infrastructure Development
Improved infrastructure includes the establishment of specialized oncology centers equipped with advanced diagnostic tools, radiation therapy facilities, and surgical capabilities necessary for comprehensive cancer care. Enhanced infrastructure facilitates timely diagnosis, accurate staging, and effective treatment delivery, thereby improving patient outcomes and survival rates. Additionally, infrastructure development supports the integration of multidisciplinary care teams, fostering collaboration among oncologists, urologists, radiologists, and support staff to optimize treatment planning and management.
Restraints/Challenges
- Limited Awareness
Limited awareness includes insufficient awareness among the general public about prostate cancer symptoms, risk factors, and the importance of early detection. Additionally, healthcare professionals may not always be fully informed about the latest advancements in mCRPC treatments, leading to delays in diagnosis and appropriate treatment initiation. Limited awareness can also affect patient advocacy efforts, funding for research, and public policy support, all of which are crucial for advancing treatment options and improving outcomes for patients with advanced prostate cancer.
- High Cost of Treatment
Advanced therapies such as immunotherapies, targeted therapies, and radioligand therapies often come with substantial price tags, making them financially burdensome for patients, healthcare providers, and payers alike. This cost barrier can limit access to cutting-edge treatments, particularly in regions with constrained healthcare budgets or for patients without adequate insurance coverage. Moreover, the high cost of treatment can strain healthcare resources and impact treatment adherence, potentially affecting patient outcomes and overall market growth.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In March 2022, Novartis received FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), previously known as 177Lu-PSMA-617, for treating prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). This innovative therapy marks the first FDA-approved targeted radioligand therapy (RLT), combining a ligand that targets PSMA with a therapeutic radioisotope. Pluvicto is designed to selectively deliver radiation to cancer cells while minimizing damage to healthy tissue
Metastatic Castrate Resistant Prostate Cancer Treatment Market Scope
The market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Hormone Therapies
- Enzalutamide
- Abiraterone
- Xofigo
- Sipuleucel-T
- Cabazitaxel
- Docetaxel
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Metastatic Castrate Resistant Prostate Cancer Treatment Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.
North America dominates the market, leading both in market share and revenue. This leadership is fueled by a high incidence of prostate cancer cases and substantial healthcare spending, which are expected to drive market growth in the region. Moreover, the emphasis of major industry players on advancing technologies is set to enhance treatment options and further bolster market expansion in North America during the forecast period.
Europe is expected to experience rapid growth in the market, driven by a high rate of cancer diagnosis across the region. The ongoing development of healthcare infrastructure and supportive government initiatives are key factors expected to accelerate market expansion. These efforts aim to enhance diagnostic capabilities and ensure broader access to advanced treatments, fostering a favorable environment for the growth of the healthcare sector and related markets in Europe.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Metastatic Castrate Resistant Prostate Cancer Treatment Market Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla (U.S.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Takeda Pharmaceutical Company Limited (Japan)
- AbbVie Inc. (U.S.)
- Merck KGaA (Germany)
SKU-